Incyte Corp (INCY) 74.65 $INCY
Incyte (INCY) Gains on Positive Baricitinib Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 4:20PM CST
Incyte (INCY) and Eli Lilly (LLY) announced encouraging results from the phase III RA-BEACON study on baricitinib.
BIIB: 344.49 (+2.16), INCY: 74.65 (-1.27), ABBV: 65.27 (-1.76), LLY: 69.55 (-2.06)
Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 10, 2:10PM CST
Yet another acquisition agreement was announced even as the biotech sector was busy with showcasing data at ASH.
BLUE: 91.28 (+5.16), BIIB: 344.49 (+2.16), VRTX: 118.55 (-2.23), CBST: 96.31 (+0.04), INCY: 74.65 (-1.27), AMGN: 164.53 (-1.55), ARRY: 4.86 (-0.04)
The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan
PR Newswire - Wed Dec 10, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Novartis (NYSE:NVS-Free Report), Amgen (Nasdaq:AMGN-Free Report), Incyte Corp. (Nasdaq:INCY-Free Report) and Allergan (NYSE:AGN-Free Report).
AGN: 208.47 (-2.67), INCY: 74.65 (-1.27), AMGN: 164.53 (-1.55), NVS: 93.52 (-0.82)
Novartis Reports Encouraging Data on Biosimilar of Neupogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 2:15PM CST
Novartis (NVS) announced that its generic arm, Sandoz, reported encouraging data from a phase III study, PIONEER.
AGN: 208.47 (-2.67), INCY: 74.65 (-1.27), AMGN: 164.53 (-1.55), NVS: 93.52 (-0.82)
Shares of INCY Up 51.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 09, 11:00AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 2 months, Incyte has returned 51.78% as of today's recent price of $77.53.
INCY: 74.65 (-1.27)
Primary endpoint achieved in baricitinib Phase 3
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 10:47AM CST
INCY: 74.65 (-1.27), LLY: 69.55 (-2.06)
Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis
PR Newswire - Tue Dec 09, 6:00AM CST
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment. The study included patients with moderately-to-severely active rheumatoid arthritis (RA) who previously failed one or more tumor necrosis factor (TNF) inhibitors and who were taking stable doses of conventional disease-modifying anti-rheumatic drug (cDMARD) therapy. The companies will share results of several ongoing Phase 3 studies in various disclosures in 2015.
INCY: 74.65 (-1.27), LLY: 69.55 (-2.06)
Hairy Cell Leukemia - Pipeline Review, H2 2014
M2 - Tue Dec 09, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/mrscnl/hairy_cell) has announced the addition of the "Hairy Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from this proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Plexxikon Inc. - Astellas Pharma Inc. - Incyte Corporation - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Inbiopro Solutions Pvt. Ltd. - Biogenomics Limited For more information visit http://www.researchandmarkets.com/research/mrscnl/hairy_cell
INCY: 74.65 (-1.27), AZN: 71.80 (-1.80), AMGN: 164.53 (-1.55), ONTX: 3.86 (-0.06), GSK: 42.42 (-0.93), STML: 16.50 (+0.31)
CURE Magazine and Incyte Honor MPN Heroes
PRWeb - Fri Dec 05, 1:31PM CST
CURE™ magazine, published by Cure Media Group, hosted the 2nd Annual MPN Heroes recognition reception honoring nine individuals in the field of myeloproliferative neoplasms (MPNs) on December 5th in San Francisco prior to the American Society of Hematology's annual meeting. The celebratory event honored this unique group of individuals who have made a difference by going above and beyond the standard of care, demonstrating leadership within the MPN community, or advancing the science of MPNs. The celebration was made possible with support from Incyte Corporation, CancerCare, Cancer Support Community, Leukemia & Lymphoma Society, MPN Advocacy & Education InternationalMPN Education Foundation, MPN Research Foundation, and MPN Education Foundation, and National Organization for Rare Disorders.
INCY: 74.65 (-1.27)
Incyte's Jakafi Gets FDA Approval for Polycythemia Vera - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 12:00PM CST
Incyte's (INCY) Jakafi gained FDA approval for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.
BIIB: 344.49 (+2.16), INCY: 74.65 (-1.27), LLY: 69.55 (-2.06), NVS: 93.52 (-0.82)
Insider Trading Alert - BRCM, LLY And INCY Traded By Insiders
at The Street - Thu Dec 04, 10:30AM CST
Stocks with insider trader activity include BRCM, LLY and INCY
BRCM: 41.64 (-1.19), INCY: 74.65 (-1.27), LLY: 69.55 (-2.06)
FDA clears Jakafi for PV
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 10:18AM CST
INCY: 74.65 (-1.27)
FDA Approves Jakafi(R) (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera
Business Wire - Thu Dec 04, 9:55AM CST
--PV is a rare blood cancer associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack(1)
INCY: 74.65 (-1.27)
1 Big FDA Decision I'm Watching This Month
Cheryl Swanson, The Motley Fool - Motley Fool - Thu Dec 04, 8:15AM CST
Biotech investing is very risky -- failures outnumber successes. Pundits like to joke that small and mid-sized biotechs should come with a black box label: WARNING: A wrong decision can cost you 90% of your investment. On the other hand, what other...
GILD: 104.13 (-0.18), INCY: 74.65 (-1.27), LLY: 69.55 (-2.06), ABBV: 65.27 (-1.76), ENTA: 43.23 (-3.20), NVS: 93.52 (-0.82)
Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 03, 9:51AM CST
Although it was a relatively uneventful week, mergers and acquisitions show no signs of slowing down in the biotech sector.
BIIB: 344.49 (+2.16), AVNR: 16.95 (-0.02), VRTX: 118.55 (-2.23), INCY: 74.65 (-1.27), ALXN: 186.90 (-4.72), PBYI: 196.34 (-7.66), REGN: 416.44 (-7.91)
Uptrend Call Working As Incyte Stock Rises 45.2% (INCY)
Comtex SmarTrend(R) - Tue Dec 02, 9:32AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 2 months, Incyte has returned 45.20% as of today's recent price of $74.17.
INCY: 74.65 (-1.27)
Multiple Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting Showcase Incyte's Leadership in the Field of Myeloproliferative Neoplasms (MPNs)
Business Wire - Tue Dec 02, 12:15AM CST
--Data from the COMFORT, JUMP, and EXPAND trials reinforce the efficacy and safety of ruxolitinib in patients with myelofibrosis (MF)
INCY: 74.65 (-1.27)
PDUFA date approaches for Jakafi label expansion myelofibrosis
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 12:43PM CST
INCY: 74.65 (-1.27)
2nd Half Of 2014 Biotechnology Catalysts: Part 5
Alexander Maxwell - at Seeking Alpha - Mon Dec 01, 8:59AM CST
BCRX: 10.06 (+0.02), CBST: 96.31 (+0.04), INCY: 74.65 (-1.27), ABBV: 65.27 (-1.76), POZN: 9.12 (-0.08), ENTA: 43.23 (-3.20)
5 Stock-Moving Medtech Events This December
at Investor's Business Daily - Fri Nov 28, 1:18PM CST
December is usually a quiet month for medical tech news, but this year will bring a few potentially stock-moving events worth keeping an eye on. As you digest your Thanksgiving turkey, here are the top five in chronological order: By Dec. 5, biotech...
SNN: 32.48 (-0.41), ESRX: 82.88 (-1.10), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), PFE: 30.95 (-0.70), MRK: 57.72 (-1.62), AZN: 71.80 (-1.80), INCY: 74.65 (-1.27), EW: 128.87 (-3.20), ABBV: 65.27 (-1.76), ENTA: 43.23 (-3.20), SYK: 92.00 (-1.41), NVS: 93.52 (-0.82)
Incyte (INCY) Gains on Positive Baricitinib Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 4:20PM CST
Incyte (INCY) and Eli Lilly (LLY) announced encouraging results from the phase III RA-BEACON study on baricitinib.
BIIB: 344.49 (+2.16), INCY: 74.65 (-1.27), ABBV: 65.27 (-1.76), LLY: 69.55 (-2.06)
Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 10, 2:10PM CST
Yet another acquisition agreement was announced even as the biotech sector was busy with showcasing data at ASH.
BLUE: 91.28 (+5.16), BIIB: 344.49 (+2.16), VRTX: 118.55 (-2.23), CBST: 96.31 (+0.04), INCY: 74.65 (-1.27), AMGN: 164.53 (-1.55), ARRY: 4.86 (-0.04)
The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan
PR Newswire - Wed Dec 10, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Novartis (NYSE:NVS-Free Report), Amgen (Nasdaq:AMGN-Free Report), Incyte Corp. (Nasdaq:INCY-Free Report) and Allergan (NYSE:AGN-Free Report).
AGN: 208.47 (-2.67), INCY: 74.65 (-1.27), AMGN: 164.53 (-1.55), NVS: 93.52 (-0.82)
Novartis Reports Encouraging Data on Biosimilar of Neupogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 2:15PM CST
Novartis (NVS) announced that its generic arm, Sandoz, reported encouraging data from a phase III study, PIONEER.
AGN: 208.47 (-2.67), INCY: 74.65 (-1.27), AMGN: 164.53 (-1.55), NVS: 93.52 (-0.82)
Shares of INCY Up 51.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 09, 11:00AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 2 months, Incyte has returned 51.78% as of today's recent price of $77.53.
INCY: 74.65 (-1.27)
Primary endpoint achieved in baricitinib Phase 3
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 10:47AM CST
INCY: 74.65 (-1.27), LLY: 69.55 (-2.06)
Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis
PR Newswire - Tue Dec 09, 6:00AM CST
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment. The study included patients with moderately-to-severely active rheumatoid arthritis (RA) who previously failed one or more tumor necrosis factor (TNF) inhibitors and who were taking stable doses of conventional disease-modifying anti-rheumatic drug (cDMARD) therapy. The companies will share results of several ongoing Phase 3 studies in various disclosures in 2015.
INCY: 74.65 (-1.27), LLY: 69.55 (-2.06)
Hairy Cell Leukemia - Pipeline Review, H2 2014
M2 - Tue Dec 09, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/mrscnl/hairy_cell) has announced the addition of the "Hairy Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from this proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Plexxikon Inc. - Astellas Pharma Inc. - Incyte Corporation - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Inbiopro Solutions Pvt. Ltd. - Biogenomics Limited For more information visit http://www.researchandmarkets.com/research/mrscnl/hairy_cell
INCY: 74.65 (-1.27), AZN: 71.80 (-1.80), AMGN: 164.53 (-1.55), ONTX: 3.86 (-0.06), GSK: 42.42 (-0.93), STML: 16.50 (+0.31)
CURE Magazine and Incyte Honor MPN Heroes
PRWeb - Fri Dec 05, 1:31PM CST
CURE™ magazine, published by Cure Media Group, hosted the 2nd Annual MPN Heroes recognition reception honoring nine individuals in the field of myeloproliferative neoplasms (MPNs) on December 5th in San Francisco prior to the American Society of Hematology's annual meeting. The celebratory event honored this unique group of individuals who have made a difference by going above and beyond the standard of care, demonstrating leadership within the MPN community, or advancing the science of MPNs. The celebration was made possible with support from Incyte Corporation, CancerCare, Cancer Support Community, Leukemia & Lymphoma Society, MPN Advocacy & Education InternationalMPN Education Foundation, MPN Research Foundation, and MPN Education Foundation, and National Organization for Rare Disorders.
INCY: 74.65 (-1.27)
Incyte's Jakafi Gets FDA Approval for Polycythemia Vera - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 12:00PM CST
Incyte's (INCY) Jakafi gained FDA approval for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.
BIIB: 344.49 (+2.16), INCY: 74.65 (-1.27), LLY: 69.55 (-2.06), NVS: 93.52 (-0.82)
Insider Trading Alert - BRCM, LLY And INCY Traded By Insiders
at The Street - Thu Dec 04, 10:30AM CST
Stocks with insider trader activity include BRCM, LLY and INCY
BRCM: 41.64 (-1.19), INCY: 74.65 (-1.27), LLY: 69.55 (-2.06)
FDA clears Jakafi for PV
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 10:18AM CST
INCY: 74.65 (-1.27)
FDA Approves Jakafi(R) (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera
Business Wire - Thu Dec 04, 9:55AM CST
--PV is a rare blood cancer associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack(1)
INCY: 74.65 (-1.27)
1 Big FDA Decision I'm Watching This Month
Cheryl Swanson, The Motley Fool - Motley Fool - Thu Dec 04, 8:15AM CST
Biotech investing is very risky -- failures outnumber successes. Pundits like to joke that small and mid-sized biotechs should come with a black box label: WARNING: A wrong decision can cost you 90% of your investment. On the other hand, what other...
GILD: 104.13 (-0.18), INCY: 74.65 (-1.27), LLY: 69.55 (-2.06), ABBV: 65.27 (-1.76), ENTA: 43.23 (-3.20), NVS: 93.52 (-0.82)
Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 03, 9:51AM CST
Although it was a relatively uneventful week, mergers and acquisitions show no signs of slowing down in the biotech sector.
BIIB: 344.49 (+2.16), AVNR: 16.95 (-0.02), VRTX: 118.55 (-2.23), INCY: 74.65 (-1.27), ALXN: 186.90 (-4.72), PBYI: 196.34 (-7.66), REGN: 416.44 (-7.91)
Uptrend Call Working As Incyte Stock Rises 45.2% (INCY)
Comtex SmarTrend(R) - Tue Dec 02, 9:32AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 2 months, Incyte has returned 45.20% as of today's recent price of $74.17.
INCY: 74.65 (-1.27)
Multiple Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting Showcase Incyte's Leadership in the Field of Myeloproliferative Neoplasms (MPNs)
Business Wire - Tue Dec 02, 12:15AM CST
--Data from the COMFORT, JUMP, and EXPAND trials reinforce the efficacy and safety of ruxolitinib in patients with myelofibrosis (MF)
INCY: 74.65 (-1.27)
PDUFA date approaches for Jakafi label expansion myelofibrosis
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 12:43PM CST
INCY: 74.65 (-1.27)
2nd Half Of 2014 Biotechnology Catalysts: Part 5
Alexander Maxwell - at Seeking Alpha - Mon Dec 01, 8:59AM CST
BCRX: 10.06 (+0.02), CBST: 96.31 (+0.04), INCY: 74.65 (-1.27), ABBV: 65.27 (-1.76), POZN: 9.12 (-0.08), ENTA: 43.23 (-3.20)
5 Stock-Moving Medtech Events This December
at Investor's Business Daily - Fri Nov 28, 1:18PM CST
December is usually a quiet month for medical tech news, but this year will bring a few potentially stock-moving events worth keeping an eye on. As you digest your Thanksgiving turkey, here are the top five in chronological order: By Dec. 5, biotech...
SNN: 32.48 (-0.41), ESRX: 82.88 (-1.10), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), PFE: 30.95 (-0.70), MRK: 57.72 (-1.62), AZN: 71.80 (-1.80), INCY: 74.65 (-1.27), EW: 128.87 (-3.20), ABBV: 65.27 (-1.76), ENTA: 43.23 (-3.20), SYK: 92.00 (-1.41), NVS: 93.52 (-0.82)
